Society guideline links: Orthopoxvirus (smallpox and mpox)

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

International

●World Health Organization (WHO): Diagnostic testing for the monkeypox virus (MPXV) – Interim guidance (2023)

●WHO: Clinical management and infection prevention and control for monkeypox – Interim rapid response guidance (2022)

●WHO: Public health advice for gatherings during the current monkeypox outbreak (2022)

●WHO: Risk communication and community engagement (RCCE) for monkeypox outbreaks – Interim guidance (2022)

●WHO: Surveillance, case investigation, and contact tracing for mpox (monkeypox) – Interim guidance (2022)

●WHO: Vaccines and immunization for monkeypox – Interim guidance (2022)

●WHO: Case definition for notification of smallpox under the IHR (2005) (published 2016)

●WHO: Smallpox – Clinical diagnosis (2016)

Canada

●Public Health Agency Canada (PHAC): Mpox (monkeypox) – Public health management of cases and contacts in Canada (2024)

●PHAC: Canadian Immunization Guide - Smallpox and monkeypox vaccine (2014, updated 2023)

●National Advisory Committee (NACI): Rapid response on interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada (2022)

●PHAC: Interim guidance on infection prevention and control for suspect, probable, or confirmed monkeypox within healthcare settings (2022)

United States

●Centers for Disease Control and Prevention (CDC): Mpox – Information for healthcare professionals

•Case definitions

•Clinical guidance

-Clinical considerations for mpox in children and adolescents

-Clinical considerations for mpox in people who are pregnant or breastfeeding

-Clinical considerations for pain management of mpox

-Clinical considerations for treatment and prophylaxis of mpox infection in people who are immunocompromised

-Clinical recognition

-Guidance for tecovirimat use

-Tecovirimat (TPOXX) for treatment of mpox

-Treatment information for healthcare professionals

•Guidelines for collecting and handling specimens for mpox testing

•Infection control

-Autopsy and handling of human remains of patients with mpox

-Infection prevention and control of mpox in healthcare settings

-Isolation and infection control at home

●CDC: Smallpox – For clinicians

•Clinical disease

•Diagnosis and evaluation

•Transmission

•Treatment

•Vaccination information

●CDC: Interim clinical considerations for use of JYNNEOS and ACAM2000 vaccines during the 2022 US mpox outbreak (2024)

●CDC: Considerations for reducing mpox transmission in congregate living settings (2023)

●Advisory Committee on Immunization Practices (ACIP): Use of JYNNEOS (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses – Recommendations, United States (2022)

●American Society of Anesthesiologists (ASA)/Anesthesia Patient Safety Foundation (APSF): Statement on monkeypox (2022)

●ACIP: Recommendations for the use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses, 2015 (published 2016)

Europe

●European Centre for Disease Prevention and Control (ECDC): Considerations for contact tracing during the monkeypox outbreak in Europe (2022)

●ECDC: Interim advice for public health authorities on summer events during the monkeypox outbreak in Europe (2022)

●ECDC: Interim advice on risk communication and community engagement during the monkeypox outbreak in Europe (2022)

●ECDC: Risk assessment – Monkeypox multi-country outbreak (2022)

●ECDC: Risk communication and community engagement approaches during the monkeypox outbreak in Europe (2022)

United Kingdom

●UK Health Security Agency (UKHSA): Mpox (monkeypox) – Guidance

•Diagnostic testing (2022, updated 2024)

•Semen testing for viral DNA (2022, updated 2024)

•Case definitions (2022, updated 2023)

•Contact tracing (2022, updated 2023)

•Principles for mpox (monkeypox) control in the UK – 4 nations consensus statement (2022, updated 2023)

•Prisons and places of detention (2022, updated 2023)

•De-isolation and discharge of mpox-infected patients (2022)

•Cleaning sex-on-premises venues (2022)

•Planning events and mass gatherings (2022)

•Vaccination strategy (2022)

•Vaccination recommendations (2022)

•Reducing risk of transmission at vaccination clinics (2022)

●British HIV Association (BHIVA): Rapid statement on monkeypox virus (2022)

●UKHSA: The Green Book – Immunisation against infectious disease: Smallpox and monkeypox (2013, updated 2022)

●BHIVA: Guidelines on the use of vaccines in HIV-positive adults – Smallpox (2015)

Australia–New Zealand

●Australian Technical Advisory Group on Immunisation (ATAGI): The Australian Immunisation Handbook – Mpox (previously known as monkeypox) (2024)

●ATAGI: Clinical guidance on vaccination against monkeypox (2022)

●Communicable Diseases Network Australia (CDNA): National guidelines for public health units on monkeypox virus infection (2022)

●Infection Prevention and Control Expert Group (ICEG): Interim guidance on monkeypox for health workers (2022)

●Public Health Laboratory Network (PHLN): Guidance on monkeypox patient referral, specimen collection and test requesting for general practitioners and sexual health physicians (2022)